ARTICLE | Clinical News

Baxter's BAX 111 meets in Phase III trial

April 16, 2014 11:44 PM UTC

Baxter International Inc. (NYSE:BAX) said on-demand treatment with IV BAX 111 given with or without the company's Advate octocog alfa met the primary endpoint in an open-label Phase III trial to treat von Willebrand disease (vWD). On-demand BAX-111 led to treatment success for treated bleeding episodes in 100% of the 22 patients who experienced bleeds during the trial. There were no reports of inhibitor development or thrombotic events. The trial enrolled 37 patients with severe hereditary vWD.

By year end, Baxter plans to submit a regulatory application to FDA for BAX 111 as an on-demand treatment for vWD. BAX 111 is a recombinant human von Willebrand factor (vWF). ...